Dear customers and partners,
at Molecular Health we share the global concern over the coronavirus pandemic. We want to assure you that we will maintain uninterrupted operation during these challenging times.
Our principal investor is Dievini, the investment company of Dietmap Hopp, focusing on innovative biotechnological products and technologies. Also in Dievini’s investment portfolio is the Tübingen-based company CureVac AG, currently in the news as they ramp up their efforts to develop an mRNA-based coronavirus vaccine.
Molecular Health’s software identifies the best drugs for individual cancer patients, and our customers – hospitals, laboratories, and patients – depend on us to continue to provide high-quality interpretation of tumours, because, especially now, all patients are entitled to the best healthcare possible.
Our software also enables pharmaceutical companies to improve their research and design more effective clinical trials.
In these times of massive transformation, we at Molecular Health have adapted our processes to protect our staff, our partners, and especially those in risk groups:
Thank you for your continued partnership, and please don’t hesitate to contact us if you have any questions or concerns.
With kind regards from Heidelberg,
Dr. Friedrich von Bohlen